Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands		Total		Impact of ASC 326 adoption	Common Stock		Retained Earnings		Retained Earnings Impact of ASC 326 adoption	Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2021	[1]				17,028,239
Beginning balance at Dec. 31, 2021	[1]	$ 120,207			$ 59,635		$ 61,746			$ (1,174)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)		(7,301)								(7,301)
Dividends payable		(1,874)					(1,874)
Restricted stock units released (in shares)					6,168
Tax benefit from restricted stock units released		(1)			$ (1)
Director stock grant		48			48
Stock-based compensation expense		53			$ 53
Net Income		2,443					2,443
Ending balance (in shares) at Mar. 31, 2022	[2]				17,034,407
Ending balance at Mar. 31, 2022	[2]	113,575			$ 59,735		62,315			(8,475)
Beginning balance (in shares) at Dec. 31, 2021	[1]				17,028,239
Beginning balance at Dec. 31, 2021	[1]	$ 120,207			$ 59,635		61,746			(1,174)
Ending balance (in shares) at Dec. 31, 2022		17,067,253			17,067,253	[3]
Ending balance at Dec. 31, 2022		$ 112,463	[3]	$ (4,678)	$ 60,030	[3]	69,928	[3]	$ (4,678)	(17,495)	[3]
Beginning balance (in shares) at Mar. 31, 2022	[2]				17,034,407
Beginning balance at Mar. 31, 2022	[2]	113,575			$ 59,735		62,315			(8,475)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)		(5,235)								(5,235)
Dividends payable		(1,875)					(1,875)
Restricted stock units released (in shares)					6,142
Director stock grant		47			$ 47
Stock-based compensation expense		53			$ 53
Net Income		3,435					3,435
Ending balance (in shares) at Jun. 30, 2022	[4]				17,040,549
Ending balance at Jun. 30, 2022	[4]	110,000			$ 59,835		63,875			(13,710)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)		(5,601)								(5,601)
Dividends payable		(1,877)					(1,877)
Restricted stock units released (in shares)					6,127
Director stock grant		44			$ 44
Stock-based compensation expense		45			$ 45
Net Income		4,467					4,467
Ending balance (in shares) at Sep. 30, 2022	[5]				17,046,676
Ending balance at Sep. 30, 2022	[5]	107,078			$ 59,924		66,465			(19,311)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)		1,816								1,816
Dividends payable		(1,878)					(1,878)
Stock options exercised (in shares)					5,579
Stock options exercised		29			$ 29
Restricted stock units released (in shares)					14,998
Director stock grant		42			$ 42
Stock-based compensation expense		35			$ 35
Net Income		$ 5,341					5,341
Ending balance (in shares) at Dec. 31, 2022		17,067,253			17,067,253	[3]
Ending balance at Dec. 31, 2022		$ 112,463	[3]	$ (4,678)	$ 60,030	[3]	69,928	[3]	$ (4,678)	(17,495)	[3]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)		639								639
Dividends payable		(1,880)					(1,880)
Restricted stock units released (in shares)					27,045
Tax benefit from restricted stock units released		(10)			$ (10)
Director stock grant		208			208
Stock-based compensation expense		41			$ 41
Net Income		$ 6,125					6,125
Ending balance (in shares) at Mar. 31, 2023		17,094,298			17,094,298	[6]
Ending balance at Mar. 31, 2023	[6]	$ 112,908			$ 60,269		$ 69,495			$ (16,856)

[1] (1) Excludes 41,424 unvested restricted shares

[2] (2) Excludes 27,949 unvested restricted shares

[3] (5) Excludes 29,449 unvested restricted shares

[4] (3) Excludes 26,949 unvested restricted shares

[5] (4) Excludes 26,949 unvested restricted shares

[6] (6) Excludes 13,974 unvested restricted shares